Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background information: Methotrexate (MTX), an anticancer drug of choice, has poor permeability across blood-brain barrier (BBB) making it unsuitable for brain tumor application. Its brain availability and scope of application was improved by preparation of reversible conjugate with lysine by capitalizing the endogenous transport system of lysine at BBB.Methods: To enhance its delivery to brain, MTX was reversibly conjugated with l-Lysine by an amide linkage. It was characterized by advanced spectroscopy techniques including IR, NMR and MS. Furthermore, conjugate was assessed for stability, toxicity and drug release ability. In vivo distribution studies were done by radioscintigraphy study using 99mTc radioisotope.Results: The structure of prodrug was confirmed by 1H-NMR, 13C-NMR and Mass. The m/e (mass to charge ratio) fragment was found at [M + H] 711.32 in Mass spectra. Stability and metabolic studies suggested that conjugate was stable at physiological pH (in Phosphate buffer pH 7.4 t1/2 is 70.25 ± 2.17 h and in plasma t1/2 is 193.57 ± 2.03 min) and circulated adequately to release MTX slowly in brain. In vivo biodistribution study showed that prodrug significantly increased the level of MTX in brain when compared with pharmacokinetic parameter of parent drug.Conclusion: The brain permeability of MTX was enhanced significantly by this conjugate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Kaminskas, L. M., Kelly, B. D., McLeod, V. M., Sberna, G., Owen, D. J., Boyd, B. J., & Porter, C. J. H. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.005 · Cited by 137 · cited 1×
“Further, lysine and its conjugates are selectively uptaken by tumor cells (Perevoshchikova, 1960; Begleiter et al., 1979; Kaminskas et al, 2011).”
Uptake of Radiolabeled Essential Amino Acids by Brain Following Arterial Injection
Oldendorf, W. H. (1971) · Experimental Biology and Medicine · doi:10.3181/00379727-136-35270 · Cited by 48
Cited by
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
“The favorable pharmacokinetics and biodistribution of the MTX-lysine conjugate demonstrated the selective brain transport of this prodrug [60].”
BackgroundKoźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103483 · Cited by 326
Pharmaceutical significance of Eudragit: A review
Patra, C. N., Priya, R., Swain, S., Kumar Jena, G., Panigrahi, K. C., & Ghose, D. (2017) · Future Journal of Pharmaceutical Sciences · doi:10.1016/j.fjps.2017.02.001 · Cited by 295
Misra, S., Chopra, K., Sinha, V. R., & Medhi, B. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1089956 · Cited by 136
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58
Metadata
- Authors
- Singh, V. K., & Subudhi, B. B.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2014-12-05
- Volume
- 23
- Issue
- 7
- Pages
- 2327-2337
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W2164508235
- Cited by
- 36
- References
- 3
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery. https://app.cochat.ai/papers/10.3109/10717544.2014.984369
- The paper
- Singh, V. K., & Subudhi, B. B. (2016). Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery. Drug Delivery. https://doi.org/10.3109/10717544.2014.984369
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.